Korean J Health Promot.  2022 Mar;22(1):40-47. 10.15384/kjhp.2022.22.1.40.

Effect of Immortal Time Bias Controlled Metformin for Cancer Development in Diabetic Patients

• Seo HJ

• KMID: 2527557
• DOI: http://doi.org/10.15384/kjhp.2022.22.1.40

Abstract

Background
This study aimed to determine the effectiveness of metformin as first line oral hypoglycemic agent in diabetes patients in inhibiting cancer incidence, on the basis of the sample cohort supplied by the National Health Insurance Service, and to ascertain the effects of time-related bias on the results.
Methods
A t-test was performed to compare the time taken for cancer development between the compliant and non-compliant metformin users and the non-metformin users. Survival analyses for cancer patients, regarding the period time until cancer incidence, were performed according to metformin use through three models: model 1 adjusted for age and sex; model 2 further adjusted for body mass index, cholesterol, and smoking status; and model 3 further adjusted for hypertension.
Results
The odds ratio for cancer development was 1.11 times higher for the non-metformin users (6,997) than for the metformin compliant users (16,132), which was significant at the 0.1 significance level. The age, sex, body mass index, cholesterol, smoking status, and hypertension-adjusted hazard ratio was 0.86.
Conclusions
This study has confirmed that metformin is effective in delaying cancer development for patients at risk of cancer rather than in inhibiting cancer incidence itself, by strict application of metformin exposure, with which immortal time biases are controlled. It is therefore necessary to manage compliance with an agent, as well as to prescribe metformin for patients at high risk of cancer, giving consideration to the risk factors for cancer development (old age, being male) instead of focusing on metformin prescription, with the objective of inhibiting cancer development.

Keyword

Diabetes mellitus; Neoplasms; Medication adherence; Selection bias; Cohort studies

Figure

• 

  Figure 1. Immortal time bias controlled model.

• 

  Figure 2. Flow diagram of study population selection.

Reference

1. Korean Diabetes Association. Korean Diabetes Fact Sheet 2018 [Internet]. Seoul: Korean Diabetes Association; 2018 [cited Dec 13, 2021]. Available from: https://www.diabetes.or.kr/bbs/index.html?sub_menu=&code=e_resource&category=1&gubun=&page=1&number=381&mode=view&order=&sort=&keyfield=&key=.

2. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002; 25(12):2244–8.

3. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012; 7(3):e33411.

4. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32(9):1620–5.

5. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011; 34(4):916–22.

6. Amshoff Y, Maskarinec G, Shvetsov YB, Raquinio PH, Grandinetti A, Setiawan VW, et al. Type 2 diabetes and colorectal cancer survival: the multiethnic cohort. Int J Cancer. 2018; 143(2):263–8.

7. Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012; 97(7):2347–53.

8. Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med. 2015; 66:17–29.

9. Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat. 2012; 135(3):639–46.

10. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist. 2012; 17(6):813–22.

11. Korean Diabetes Association. Korean Diabetes Fact Sheet 2015 [Internet]. Seoul: Korean Diabetes Association; 2016 [cited Dec 13, 2021]. Available from: https://www.diabetes.or.kr/bbs/index.html?sub_menu=&code=e_resource&category=1&gubun=&page=1&number=292&mode=view&order=&sort=&keyfield=&key=.

12. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012; 35(12):2665–73.

13. Song SO. Correlation Study between Diabetes and Cancer Development [Internet]. Goyang: National Health Insurance Service Ilsan Hospital; 2017 [cited Dec 13, 2021]. Available from: https://www.nhimc.or.kr/openInfo/management/audit/hospital_41_disc_audit05_1.do.

14. Hwangbo Y, Kang D, Kang M, Kim S, Lee EK, Kim YA, et al. Incidence of diabetes after cancer development: a Korean national cohort study. JAMA Oncol. 2018; 4(8):1099–105.

15. Mi X, Hammill BG, Curtis LH, Greiner MA, Setoguchi S. Impact of immortal person-time and time scale in comparative effectiveness research for medical devices: a case for implantable cardioverter-defibrillators. J Clin Epidemiol. 2013; 66(8 Suppl):S138–44.

16. Karim ME, Gustafson P, Petkau J, Tremlett H; Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study Group. Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies. Am J Epidemiol. 2016; 184(4):325–35.

17. Agarwal P, Moshier E, Ru M, Ohri N, Ennis R, Rosenzweig K, et al. Immortal time bias in observational studies of time-to-event outcomes: assessing effects of postmastectomy radiation therapy using the national cancer database. Cancer Control. 2018; 25(1):1073274818789355.

18. Hong JS, Kang HJ, Park JH, Lee YM. Analysis of Prescription Status and Medication Compliance of Diabetic Patients [Internet]. Seoul: Health Insurance Review and Assessment Service; 2009 [cited Dec 13, 2021]. Available from: http://dlps.nanet.go.kr/SearchDetailView.do?cn=MONO1201012639&sysid=nhn.

19. Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017; 60(9):1586–93.

20. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29(2):254–8.

21. Bosco JL, Antonsen S, Sørensen HT, Pedersen L, Lash TL. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev. 2011; 20(1):101–11.

22. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007; 16(3):241–9.

23. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010; 340:b5087.

24. Jones M, Fowler R. Immortal time bias in observational studies of time-to-event outcomes. J Crit Care. 2016; 36:195–9.

25. Cayea D, Boyd C, Durso SC. Individualising therapy for older adults with diabetes mellitus. Drugs Aging. 2007; 24(10):851–63.

26. Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother. 2009; 7(6):324–42.

27. Park SC, Kim DU, Park JE, Kim JJ, Lee SM. Analysis of the correlation between smoking and lung cancer and risk factors for lung cancer in Koreans. Goyang: NHIS Ilsan Hospital National Health Insurance Service Ilsan Hospital;2016.

28. Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh DP, Chen CC. Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer. 2012; 13(2):143–8.

29. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019; 394(10204):1159–68.

30. Choi IS, Oh CH, Park SY, Ahn SE, Park SJ, Choi HR, et al. Incidence of primary liver cancer in subjects with chronic hepatitis B in Korean national liver cancer screening program. J Liver Cancer. 2017; 17(2):136–43.